Salbutamol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Salbutamol: From Bronchodilator (Asthma/COPD) to Papillary Conjunctivitis
One-Sentence Summary
Salbutamol is a short-acting β2-adrenergic agonist whose established clinical role — confirmed elsewhere in this same evidence pack — is as a bronchodilator for obstructive airway disease (asthma/COPD). The TxGNN model’s top-ranked prediction for this drug is Papillary Conjunctivitis, but this candidate is currently supported by 0 clinical trials and 0 publications — it is a pure model score with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma / COPD (bronchodilator); formal SAHPRA-approved indication text not available in this evidence pack (data gap) |
| Predicted New Indication | Papillary Conjunctivitis |
| TxGNN Prediction Score | 99.996% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for salbutamol is not available in this evidence pack (flagged as a High-severity data gap). Based on information available elsewhere in this same pack, salbutamol is a selective β2-adrenergic receptor agonist that relaxes bronchial smooth muscle — this is its well-established, core clinical use in obstructive airway disease (asthma/COPD), not a “repurposed” indication.
Papillary conjunctivitis, by contrast, is predominantly a mechanically and allergen-driven condition (commonly associated with contact lens wear or ocular foreign-body irritation), rather than a disorder primarily mediated through β2-adrenergic smooth-muscle or vascular pathways. The evidence pack’s own analysis of this candidate explicitly flags the mechanistic link as weak, and no clinical trials or literature — direct or indirect — were retrieved to support it.
For context, a related but distinct condition in this same evidence pack, atopic/allergic conjunctivitis, does have older animal-model literature (1980s) suggesting β2-agonists including salbutamol can suppress immediate allergic conjunctival reactions via conjunctival mast cell and vascular β2-receptors. That evidence does not transfer directly to papillary conjunctivitis, which is a separate, largely non-allergic mechanical entity, and should not be read as support for this specific candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Salbutamol is not currently registered or marketed under SAHPRA according to this evidence pack (0 registrations, market status: not marketed). No product/registration records are available to summarize.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there is zero clinical trial or literature support, and the proposed mechanism does not clearly align with the mechanical/allergen-driven pathophysiology of papillary conjunctivitis. Combined with the drug’s unmarketed status in South Africa, this candidate does not meet the threshold to advance.
To proceed, the following is needed:
- Confirmed original indication and mechanism-of-action data (currently a data gap)
- SAHPRA Professional Information (warnings/contraindications), currently unavailable
- Preclinical or mechanistic studies specifically testing salbutamol in papillary conjunctivitis (contact lens–associated or allergic models)
- Any clinical case series or trial data directly addressing this indication before further evaluation
Note: Other predicted indications for salbutamol in this same evidence pack carry substantially stronger evidence and may warrant separate, prioritized evaluation — notably obstructive lung disease (L1, Proceed with Guardrails, though this reflects the drug’s already-known core use rather than true repurposing) and bronchitis (L2, Proceed with Guardrails).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.